Treating Gum Disease At Home Does Not Have To Be Complicated. Especially when you are given step by step instructions on what to do.
This video gives you a complete gum disease healing programme that you need to follow strictly if you want to see results.
In 3-6 months time you should be gum disease free but only if you stick to this programme and don't deviate!
Below you will find links to some useful resources and products you will need to start this healing programme:
Blotting technique for teeth video: https://www.youtube.com/watch?v=pcu8q1PwI6o
Pure Acerola Powder for Vitamin C: https://amzn.to/2uphcbs
Cod Liver Oil For Vitamin A & D: https://amzn.to/38VmIlc
White Oak Powder: https://amzn.to/2HNMuvB
Sea Salt: https://amzn.to/2HONa41
http://www.cannonraceway.co.uk/ Cannon Raceways offers superb kart racing packages perfect for birthday, stag or hen parties, work outings or any other form of celebration. Karting is an excellent team building exercise and perfect for treating your staff to a fun day out. For those who want to test out our kart track before going for the real race, our track drive experience is a must. Ideal for people who have never been karting before or for those who want to improve their kart racing skills. As the UK’s number one kart track we are conveniently located just five minutes from the M6 junction 10 and the M5 junction 2, just a short drive from Birmingham, Wolverhampton, Stourbridge, Walsall, Oldbury and Halesowen.
http://www.unitetheunion.org BA represents a great British tradition. Unfortunately, Willie Walsh doesnt get it. After taking lawful strike action for the first time in many years, we are being victimized. Brutish Airways is treating us like trash, but we wont give in to a bully. Help us fly the flag and get BA airborne again.
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
